Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis

Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown promising results in a small group of systemic lupus erythematosus (SLE) patients treated for lupus nephritis (LN). However, such observations were not confirmed in the double-blind LUNAR study. Accordingly, the factors associated with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Seret, Guillaume, Hanrotel, Catherine, Bendaoud, Boutahar, Le Meur, Yannick, Renaudineau, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094396/
https://www.ncbi.nlm.nih.gov/pubmed/27818754
http://dx.doi.org/10.1093/ckj/sfs162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094396/
https://www.ncbi.nlm.nih.gov/pubmed/27818754
http://dx.doi.org/10.1093/ckj/sfs162

Ejemplares similares